ISDA

Deposition Date 2009-12-10

Release Date 2010-02-16

Last Version Date 2023-09-06

Entry Detail

PDB ID:

3L13

Keywords:

TRANSFERASE

Title:

Crystal Structures of Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.00 Å

R-Value Free:

0.27

R-Value Work:

0.23

R-Value Observed:

0.23

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Gene (Uniprot):PIK3CG
Chain IDs:A
Chain Length:960
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P48736 Pfam ID:PF00794, PF00792, PF00613, PF00454 EC:2.7.1.137

Ligand Molecules

JZW

Primary Citation

Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer.

Sutherlin, D.P, Sampath, D, Berry, M, Castanedo, G, Chang, Z, Chuckowree, I, Dotson, J, Folkes, A, Friedman, L, Goldsmith, R, Heffron, T, Lee, L, Lesnick, J, Lewis, C, Mathieu, S, Nonomiya, J, Olivero, A, Pang, J, Prior, W.W, Salphati, L, Sideris, S, Tian, Q, Tsui, V, Wan, N.C, Wang, S, Wiesmann, C, Wong, S, Zhu, B.Y.Show

J.Med.Chem. 53 1086 1097 (2010)

PMID: 20050669 DOI: 10.1021/jm901284w

Abstact

The PI3K/AKT/mTOR pathway has been shown to play an important role in cancer. Starting with compounds 1 and 2 (GDC-0941) as templates, (thienopyrimidin-2-yl)aminopyrimidines were discovered as potent inhibitors of PI3K or both PI3K and mTOR. Structural information derived from PI3K gamma-ligand cocrystal structures of 1 and 2 were used to design inhibitors that maintained potency for PI3K yet improved metabolic stability and oral bioavailability relative to 1. The addition of a single methyl group to the optimized 5 resulted in 21, which had significantly reduced potency for mTOR. The lead compounds 5 (GNE-493) and 21 (GNE-490) have good pharmacokinetic (PK) parameters, are highly selective, demonstrate knock down of pathway markers in vivo, and are efficacious in xenograft models where the PI3K pathway is deregulated. Both compounds were compared in a PI3K alpha mutated MCF7.1 xenograft model and were found to have equivalent efficacy when normalized for exposure.

Legend

Protein

Chemical

Disease

Primary Citation of related structures